Valneva and Dynavax announced commercial supply agreement for inactivated, adjuvanted COVID-19 vaccine
On Sept. 14, 2020, Dynavax Technologies announced a commercial partnership for the supply of Dynavax’s CpG 1018 adjuvant…
-
-
COVID-19 vaccine AZD1222 clinical trials resumed in the UK
On Sept. 12 2020, Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK…
-
MediciNova announced intranasal RS virus vaccine vuccessfully induced neutralizing antibodies against RS virus in mice
On Sept. 11, 2020, MediciNova announced development progress on its intranasal SARS-CoV-2 vaccine for COVID-19 utilizing BC-PIV, a…
-
Merck announced positive topline results from phase 3 adult studies evaluating investigational 15-valent pneumococcal conjugate vaccine
On Sept. 9, 2020, Merck announced announced that two Phase 3 studies evaluating the safety, tolerability and immunogenicity…
-
AstraZeneca Oxford SARS-CoV-2 vaccine, AZD1222, COVID-19 vaccine trials temporary paused
On Sept. 9, 2020, as part of the ongoing randomised, controlled clinical trials of the AstraZeneca Oxford coronavirus…
-
Sinovac reported preliminary phase I/II results of COVID-19 vaccine in elderly volunteers
On Sept. 9, 2020, Sinovac Biotech announced that the inactivated COVID-19 vaccine candidate developed by Sinovac Life Sciences…
-
The ACIP updated flu vaccine recommendations for 2020-2021
On Sept. 9, 2020, the American Academy of Family Physicians (AAFP) reviewed and agreed with the Advisory Committee…
-
Valneva announced IXIARO supply contract with the U.S. Government worth up to $166 million
On Sept. 9, 2020, Valneva announced the signing of a new contract, lasting up to three years, with…
-
Pfizer and BioNTech announced data from preclinical studies of mRNA-based vaccine candidate against COVID-19
On Sept. 9, 2020, Pfizer and BioNTech announced preliminary preclinical data in mouse and non-human primate models from…
-
Pfizer and BioNTech to potentially supply EU with 200 million doses of mRNA-based vaccine candidate against SARS-CoV-2
On Sept. 9, 2020, Pfizer and BioNTech announced that they had submitted an amended protocol to the FDA…
-
BioNTech and Pfizer announced data from preclinical studies of mRNA-based vaccine candidate against COVID-19
On Sept. 9, 2020, Pfizer and BioNTech announced preliminary preclinical data in mouse and non-human primate models from…
-
iBio advanced COVID-19 LicKM-subunit vaccine candidate, IBIO-201
On Sept. 9, 2020, iBio announced that it had selected IBIO-201, its LicKMﾙ-ubunit vaccine, as its leading candidate…
-
INOVIO added Thermo Fisher Scientific to global manufacturing consortium
On Sept. 8, 2020, INOVIO announced that Thermo Fisher Scientific, the world leader in serving science, had signed…
-
Biopharma leaders united to stand with science
On Sept. 8, 2020, the CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, and…
-
Vaxartﾒs oral COVID-19 vaccine candidate induced potent systemic and mucosal immune responses in preclinical studies
On Sept. 8, 2020, Vaxart announced pre-publication of a manuscript titled ﾓPreclinical studies of a recombinant adenoviral mucosal…
-
BioNTech and Pfizer receive regulatory approval to commence global phase 2/3 trial for COVID-19 vaccine candidate
On Sept. 7, 2020, Pfizer and BioNTech announced that the German regulatory authority, the Paul-Ehrlich-Institut, had approved the…
-
US Departments of HHS and DoD announced collaboration with McKesson for COVID-19 vaccine distribution
On Sept. 4, 2020, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DoD),…
-
Johnson & Johnson announced COVID-19 investigational vaccine candidate prevents severe clinical disease in hamsters
On Sept. 3, 2020, as part of the ongoing randomised, controlled clinical trials of the AstraZeneca Oxford coronavirus…
-
U.S. Department of Defense sites selected for phase III COVID-19 vaccine trials
On Sept. 3, 2020, the U.S Department of Defense announced that five locations were identified to participate in…
-
Sanofi and GSK initiated Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
On Sept. 3, 2020, Sanofi and GSK announced the start of the Phase 1/2 clinical trial for their…
-
COVID-19 vaccine study shows severe disease preventable in hamsters
On Sept. 3, 2020, Oregon Health & Science University (OHSU) announced that for the first time, early research…
-
RedHill Biopharma’s Opaganib awarded COVID-19 grant by State of Pennsylvania
On Sept. 3, 2020, RedHill Biopharma announced the selection of opaganib, a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2)…
-
Novavax announced publication of phase 1 data for COVID-19 vaccine candidate in The New England Journal of Medicine
On Sept. 2, 2020, Novavax announced the publication in The New England Journal of Medicine of Phase 1…
-
Aegis Life launched to fight COVID-19 via DNA vaccines and therapeutics enabled by Fusogenix delivery technology
On Sept. 1, 2020, Entos Pharmaceuticals announce the launch of its San Diego-based spinout company Aegis Life, dedicated…
-
MediciNova announced development progress on intranasal formulation of SARS-CoV-2 vaccine for COVID-19
On Sept. 1, 2020, MediciNova announced development progress on its intranasal SARS-CoV-2 vaccine for COVID-19 utilizing BC-PIV, a…
-
HDT BIO received NIH contract to advance novel RNA/LIONﾙ COVID-19 vaccine into clinical trials
On Sept. 1, 2020, HDT Bio received a notice of award from the National Institute of Allergy and…
-
Phase 3 clinical testing in the US of AstraZeneca COVID-19 vaccine candidate began
On Aug. 31, 2020, a multi-site, Phase 3 clinical trial evaluating an investigational COVID-19 vaccine known as AZD1222…
-
Development of COVID-19 vaccine AZD1222 expanded into U.S. Phase III clinical trial across all adult age groups
On Aug. 31, 2020, AstraZeneca announced that the COVID-19 vaccine AZD1222 expanded into U.S. Phase III clinical trial…
-
Novavax and Canada reached agreement to acquire Novavax COVID-19 vaccine
On Aug. 31, 2020, Novavax announced it had reached an agreement in principle with the Government of Canada…
-
Moderna confirmed discussions with the MHLW to supply Japan with 40 million doses of mRNA vaccine against COVID-19
On Aug. 28, 2020, Moderna confirmed that the Company was engaged in discussions with the Ministry of Health,…
